250 related articles for article (PubMed ID: 26765315)
21. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
LoRusso PM; Rudin CM; Reddy JC; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Chang I; Darbonne WC; Graham RA; Zerivitz KL; Low JA; Von Hoff DD
Clin Cancer Res; 2011 Apr; 17(8):2502-11. PubMed ID: 21300762
[TBL] [Abstract][Full Text] [Related]
22. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
Lyons TG; O'Kane GM; Kelly CM
Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
[TBL] [Abstract][Full Text] [Related]
24. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A; Jensen R; Friedman R
BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
[TBL] [Abstract][Full Text] [Related]
25. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma.
Basset-Seguin N; Sharpe HJ; de Sauvage FJ
Mol Cancer Ther; 2015 Mar; 14(3):633-41. PubMed ID: 25585509
[TBL] [Abstract][Full Text] [Related]
27. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
28. Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function.
Moutasim KA; Mellows T; Mellone M; Lopez MA; Tod J; Kiely PC; Sapienza K; Greco A; Neill GW; Violette S; Weinreb PH; Marshall JF; Ottensmeier CH; Sayan AE; Jenei V; Thomas GJ
J Pathol; 2014 Jun; 233(2):196-208. PubMed ID: 24573955
[TBL] [Abstract][Full Text] [Related]
29. [Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells].
Huang XB; Shi Y; Wang CS; Wang XD; Cheng J; Che FF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1459-1465. PubMed ID: 27784375
[TBL] [Abstract][Full Text] [Related]
30. Arsenic Trioxide inhibits Activation of Hedgehog Pathway in Human Neuroblastoma Cell Line SK-N-BE(2) Independent of Itraconazole.
Liu X; Wang Z; Xiong X; Li C; Wu Y; Su M; Yang S; Zeng M; Weng W; Huang K; Zhou D; Fang J; Xu L; Li P; Zhu Y; Qiu K; Ma Y; Lei J; Li Y
Anticancer Agents Med Chem; 2023; 23(20):2217-2224. PubMed ID: 37888819
[TBL] [Abstract][Full Text] [Related]
31. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
[TBL] [Abstract][Full Text] [Related]
32. Can hair re-growth be considered an early clinical marker of treatment resistance to Hedgehog inhibitors in patients with advanced basal cell carcinoma? A report of two cases.
Soura E; Plaka M; Dessinioti C; Syrigos K; Stratigos AJ
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1726-1729. PubMed ID: 27461144
[TBL] [Abstract][Full Text] [Related]
33. Itraconazole in the treatment of basal cell carcinoma: A case-based review of the literature.
Ip KH; McKerrow K
Australas J Dermatol; 2021 Aug; 62(3):394-397. PubMed ID: 34160825
[TBL] [Abstract][Full Text] [Related]
34. Cross-Talk between Wnt and Hh Signaling Pathways in the Pathology of Basal Cell Carcinoma.
Noubissi FK; Yedjou CG; Spiegelman VS; Tchounwou PB
Int J Environ Res Public Health; 2018 Jul; 15(7):. PubMed ID: 29987229
[TBL] [Abstract][Full Text] [Related]
35. [Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
Guo W; Tang XD; Tang S; Yang Y
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(12):805-8. PubMed ID: 16889724
[TBL] [Abstract][Full Text] [Related]
36. Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy.
Paret C; Theruvath J; Russo A; Kron B; El Malki K; Lehmann N; Wingerter A; Neu MA; Gerhold-Ay A; Wagner W; Sommer C; Pietsch T; Seidmann L; Faber J
Oncotarget; 2016 Dec; 7(50):83378-83391. PubMed ID: 27825128
[TBL] [Abstract][Full Text] [Related]
37. Loss of protein kinase Calpha expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma.
Neill GW; Ghali LR; Green JL; Ikram MS; Philpott MP; Quinn AG
Cancer Res; 2003 Aug; 63(15):4692-7. PubMed ID: 12907651
[TBL] [Abstract][Full Text] [Related]
38. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
39. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
40. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
